#344 Statins in Older Adults
CLINICAL QUESTION
In patients ≥65 years old, do the benefits of statins outweigh harms?
BOTTOM LINE
For primary prevention patients aged 65-75 years, statins likely result in a 16-39% relative reduction in major adverse cardiac events (MACE). For primary prevention patients aged >75, the benefit of initiating statins is unclear. However, there is no evidence to support stopping statins when primary prevention patients age over 75 (just because of age). For secondary prevention patients over 65 years (and over 75), statins result in ~20% relative reduction in MACE. Adverse events are similar to placebo.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Seven systematic reviews1-7 of randomized controlled trials (RCTs) in a population age ≥65.
- Largest systematic review (26 RCTs, 186,854 patients, follow-up ~5 years) reported individualized patient data and analyzed by age (5-year categories) and by primary and secondary prevention.¹
- Results statistically significant, unless stated.
- Primary prevention:
- Major adverse cardiac events (largest systematic review):¹
- Patients >65 to <70 years: Relative risk (RR)=0.61 (0.51-0.73)
- Patients >70 to <75 years: RR=0.84 (0.70-1.01)
- Patients >75 years: RR=0.92 (0.73-1.16)
- Another systematic review² found >65 (mean age 73): RR=0.82 (0.74-0.92)
- Statins benefit on MACE appears to diminish in advanced age, with benefits likely extending to age 75. Beyond 75 years, uncertainty exists.
- Mortality: No difference in all-cause mortality.2-4
- Major adverse cardiac events (largest systematic review):¹
- Secondary prevention:
- MACE: ~20% relative benefit across all ages,1 for example,
- Patients 66-70 years: 4.3% versus 5.6% annually.¹
- Patients age >75 years: 6.0% versus 6.8% annually.¹
- Mortality: ~20% relative benefit in all-cause mortality.3,5
- MACE: ~20% relative benefit across all ages,1 for example,
- Adverse events:
- No difference in overall,6 serious,2,6 or discontinuation due to adverse events.2,6
- While an early RCT7 and systematic review8 raised concerns about increased cancer risk, subsequent studies do not support this risk.1,4,9
- No RCTs/observational evidence of association between statins and dementia.10
- No difference in overall,6 serious,2,6 or discontinuation due to adverse events.2,6
- Guideline definitions and recommendations vary for older adults.11-15
- MACE definitions vary between studies.
- Upcoming key trials:
- STAREE:16 ~10,000 primary prevention patients >70 years old determining effect of atorvastatin on death, disability, and MACE.
- SITE:17 ~1200 primary prevention patients >75 years determining effect of stopping statins on all-cause mortality.
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
Good to know about the age cutoffs where statin primary prevention might be useful. This seems to come up a lot in clinic and hospital setting!
Excellent perspective – need to factor in absolute risk as well but it has been easy to exagerrate the relative risk at times.